Stock CURE KINARUS THERAPEUTICS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Kinarus Therapeutics Holding AG Stock

Equities

CURE

CH0009115129

Delayed Swiss Exchange
Other stock markets
 11:31:59 2024-04-30 am EDT 		5-day change 1st Jan Change
16.25 CHF -2.99% Intraday chart for Kinarus Therapeutics Holding AG +0.76% +806.81%
Apr. 26 Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis MT
Apr. 25 Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction. CI

Chart Kinarus Therapeutics Holding AG

Dynamic Chart

Latest news about Kinarus Therapeutics Holding AG

Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis MT
Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction. CI
Swiss Exchange Regulator Drops Inquiry Into Kinarus Therapeutics MT
Kinarus Therapeutics Receives Swiss Court Approval for Revocation of Bankruptcy MT
Kinarus Therapeutics Shares Surge on Combination Deal With Curatis MT
Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG in a reverse merger transaction. CI
Kinarus Therapeutics to File for Bankruptcy After Funding Efforts Fail MT
Kinarus Therapeutics' H1 Loss Widens MT
Kinarus Therapeutics Sells License for Lung Disease Treatment to Shareholder Group MT
Kinarus Therapeutics Holding AG Signs Licensing Agreement to Extend Cash for Operations CI
Kinarus Therapeutics’ Interim CFO Steps Down MT
Kinarus Therapeutics Announces Personnel Changes CI
Kinarus Therapeutics Secures Liquidity via Subordinated Bridge Loan Deals MT
Kinarus Therapeutics Posts Higher FY22 Attributable Loss MT
SIX Exchange Probes Kinarus Therapeutics Over Potential Disclosure Violation MT
More news

Press releases Kinarus Therapeutics Holding AG

Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed EQ
Kinarus Therapeutics : Q&A on the Reverse Share Split PU
Kinarus Therapeutics : Q&A on the Reverse Share Split” unter Financial News / Corporate News ablegen PU
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split EQ
Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis EQ
More press releases

News in other languages on Kinarus Therapeutics Holding AG

Bourse Zurich: le SMI se maintient dans le vert avant l'inflation US
Bourse Zurich: rebond dans les premiers échanges, l'inflation US attendue
Bourse Zurich: un rebond escompté en entame de séance
Curatis (Kinarus) à l'aube de son premier jour de négoce
Bourse Zurich: les indices effacent une partie des pertes de la veille
More news

Quotes and Performance

1 day-2.99%
1 week+0.76%
Current month-21.15%
1 month-17.56%
3 months-4.55%
6 months+504.54%
Current year+806.81%
More quotes

Highs and lows

1 week
14.34
Extreme 14.336
18.00
1 month
13.44
Extreme 13.44
20.61
Current year
1.79
Extreme 1.792
33.15
1 year
0.90
Extreme 0.896
59.14
3 years
0.90
Extreme 0.896
230.27
5 years
0.90
Extreme 0.896
230.27
10 years
0.90
Extreme 0.896
230.27
More quotes

Company Profile

Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. CURE Stock